期刊文献+

冠心病患者血小板活化因子在药物洗脱支架置入前后的变化及意义 被引量:5

Change of level of platelet activating factor after drug eluting stent implantation in patients with stable coronary heart disease and its significance
下载PDF
导出
摘要 目的:比较稳定型冠心病患者动脉血浆血小板活化因子(PAF)浓度在药物洗脱支架(DES)置入前、后的变化,探讨基线PAF水平与心血管事件的关系。方法:2007年8月至2008年12月,入选88例稳定冠心病患者,收集其临床、冠脉造影(CAG)和经皮冠脉介入治疗(PCI)资料。所有入选者均采用酶联免疫吸附法测定PCI前留取的动脉(主动脉根部)血浆PAF水平。根据基线PAF水平分层,随访1年时的死亡、非致死性急性冠脉综合征(ACS)、再次PCI、再次心血管原因入院等主要不良心血管事件。29例稳定冠心病患者在DES置入平均8个月后进行了CAG复查和PAF水平测定。结果:DES置入8个月后随访PAF浓度明显低于基线水平[(236.25±17.78)pg/ml∶(349.92±38.44)pg/ml,P=0.0109]。平均随访12.5月,PAF高水平(PAF≥260pg/ml)组死亡、非致死性ACS、再入院和再次PCI联合终点心血管事件较低水平(PAF〈260pg/ml)组明显增多(RR=1.714,95%CI:1.051~2.796,P=0.031)。结论:稳定冠心病患者血小板活化因子水平与短期内主要不良心血管事件有关;药物洗脱支架置入8个月后血小板活化因子水平明显降低,可能与其有效地抑制了炎症反应和降低了血小板的激活有关。 Objective: To compare plasma levels of platelet activating factor(PAF) before and after drug eluting stent(DES) implantation in patients with stable coronary heart disease(CHD),and explore the association between baseline PAF level and cardiovascular events.Methods: A total of 88 cases with stable CHD were enrolled from August 2007 to December 2008.Data of clinical characteristics,coronary angiography(CAG) and percutaneous coronary intervention(PCI) were collected in these patients.Enzyme linked immunosorbent assay was used to measure plasma level of PAF(aortic root) in all patients before PCI.According to stratification of baseline PAF level,patients were followed up to one year after PCI for main cardiovascular events.After DES implantation for a mean eight months,29 patients with stable CHD were measured for CAG and PAF again.Results: After DES implantation eight months,PAF concentration was significantly lower than baseline level [(236.25±17.78)pg/ml vs.(349.92±38.44)pg/ml,P=0.0109].After follow up to mean 12.5 months,combine end-point of cardiovascular events(death,nonfatal ACS,repeated PCI and rehospitalization)significantly increased in high PAF level(PAF≥260pg/ml)group compared with that in low PAF level(PAF260pg/ml)group(RR=1.714,95%CI:1.051~2.796,P=0.031).Conclusion: PAF level in patients with stable CHD is related with short-term main cardiovascular events.After DES implantation eight months,PAF level significantly decreases which might be attributed to inhibition of inflammatory reaction and activation of platelet.
出处 《心血管康复医学杂志》 CAS 2011年第2期109-113,共5页 Chinese Journal of Cardiovascular Rehabilitation Medicine
关键词 冠状动脉疾病 血小板活化因子 支架 Coronary artery disease Platelet activating factor Stents
  • 相关文献

参考文献13

  • 1王兆钺.血小板与凝血因子的相互作用及其意义[J].中华血液学杂志,2004,25(3):187-189. 被引量:28
  • 2殷兆芳,吴士尧,严毓勤,解玉水,程纯.血管性血友病因子基因19内含子MspⅠ多态性与冠心病危险因素的关系[J].临床心血管病杂志,2004,20(2):73-75. 被引量:4
  • 3Kulkarni S, Wooltard KJ, Thomas S, et al. Conversion of platelets from a proaggregatory to a proinflammatory adhesive phenotype: role of PAF in spatially regulating neutrophil adhesion and spreading [J]. Blood, 2007, 110 (6).- 1879--1886.
  • 4Zimmerman GA, Mclntyre TM, Prescott SM, et al. The platelet-activating factor signaling system and its regulatiors in syndromes of inflammation and thrombosis [J]. Crit Care Med, 2002, 30 (5S): S294--S301.
  • 5White MC, McHowat J. Protease activation of calcium--independent phospholipase A2 leads to neutrophil recruitment to coronary artery endothelial cells [J]. Thromh Res, 2007, 120 (4) : 597--605.
  • 6Mueller HW, Haught CA, McNatt JM, et al. Measurement of platelet-activating factor in a canine model of coronary thrombosis and in endarterectomy samples from patients with advanced coronary artery disease [J]. Cire Res, 1995, 77 (1): 54--63.
  • 7Kounis NG, Hahalis G, Theoharides TC. Coronary stents, hypersensitivity reactions, and the Kounis syndrome [J]. J IntervCardiol, 2007, 20 (5).. 314--323.
  • 8Crawford SE, Huang L, Hsueh W, et al. Captopril and platelet--activating factor (PAF) antagonist prevent cardiac allograft vasculopathy in rats., role of endogenous PAF and PAF--like compounds [J]. J Heart Lung Transplant, 1999, 18 (5) : 470 --477.
  • 9Tselepis AD, Goudevenos JA, Tambaki AP, et al. Platelet aggregatory response to platelet activating factor (PAF), ex vivo, and PAF--aeetylhydrolase aetivity in patients with unstable angina: effect of c7E3 Fab (abeiximab) therapy[J]. Cardiovase Res, 1999, 43 (1): 183--191.
  • 10Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women with elevated C--reactive protein [J]. N Engl J Med, 2008, 359 (21): 2195-- 2207.

二级参考文献5

共引文献29

同被引文献44

引证文献5

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部